Chapter 36 Pain Management during Pregnancy and Lactation Flashcards Preview

Essentials of Pain Medicine > Chapter 36 Pain Management during Pregnancy and Lactation > Flashcards

Flashcards in Chapter 36 Pain Management during Pregnancy and Lactation Deck (59):
1

Diffusion

primarily passive and the drug concentration in the umbilical vein or breast milk depends on the concentration gradient, drug lipid solubility, degree of ionization and protein binding, and the diffusion capacity of the membrane (this may change as pregnancy progresses).

2

The effects of the drugs on
the fetus or nursing child will depend on

the gestational or postconceptual age, as well as the amount and duration of
drug exposure, and the specific drug

3

physiologic changes of pregnancy influence
drug absorption, distribution, and elimination

Changes in gastrointestinal function can alter oral drug absorption. Renal elimination is generally increased because of
an increase in glomerular filtration rate. Hepatic metabolism may be increased, unchanged, or decreased, and the increase in total body water may alter drug distribution
and peak concentrations. Protein binding is usually
decreased; however, the free drug concentration may be
unchanged because of increased drug clearance.

4

The amount of drug that crosses the placenta depends on

maternal cardiac output, fetal cardiac output, placental binding, and placental metabolism, as well as factors that influence passive diffusion across the placenta

5

Maternal plasma levels of a drug depend on

the site of administration
(e.g., oral, intravascular, or epidural space), the total dose,
the dosing interval, and other drugs that may be co-administered (e.g., epinephrine)

6

The amount of drug to which
the fetus is exposed also depends on

fetal metabolism (fetal
blood carrying drugs away from the placenta passes first through the fetal liver), fetal protein binding (about half of
maternal protein binding), and the distribution of fetal
cardiac output (fetal distress results in redistribution of
blood flow to the vital organs).

7

Possible adverse effects on the fetus of in utero drug exposure include

structural malformations, intrauterine fetal death, altered fetal growth, neurobehavioral teratogenicity, acute neonatal intoxication or neonatal abstinence syndromes

8

A major determinant of the effect of a drug on the
fetus is the

gestational age of the fetus.

9

The period of classic teratogenesis

corresponds with the critical period of organogenesis and begins approximately 31 days after the first day of the last menstrual period until about 71 days after the last period.

10

fetal drug exposure at this
time is not risk free.

Fetal development, particularly the central nervous system,
continues into the second and third trimesters, and
indeed after birth.

11

U.S. Food and Drug Administration Pregnancy Category System - A

Adequate, well-controlled studies in pregnant women have not shown
an increased risk of fetal abnormalities

12

U.S. Food and Drug Administration Pregnancy Category System- B

Animal studies have revealed no harm to the fetus; however, there are no
adequate and well-controlled studies in pregnant women. Or animal studies
have shown an adverse effect, but adequate and well-controlled studies in
pregnant women have failed to demonstrate a risk to the fetus

13

U.S. Food and Drug Administration Pregnancy Category System- C

Animal studies have shown adverse fetal effects and there are no adequate
and well-controlled studies in pregnant women. Or no animal studies have
been conducted and there are no adequate and well-controlled studies in
pregnant women.

14

U.S. Food and Drug Administration Pregnancy Category System- D

Studies, adequate and well controlled or observational, in pregnant women
have demonstrated a risk to the fetus. However, the benefits of therapy may
outweigh the potential risk.

15

U.S. Food and Drug Administration Pregnancy Category System- X

Studies, adequate and well controlled or observational, in animals and pregnant
women have demonstrated positive evidence of fetal abnormalities. The use of
the product is contraindicated in women who are or may become pregnant.

16

U.S. Food and Drug Administration Pregnancy Category System- B
Drugs

Acetaminophen; butorphanol, nalbuphine; caffeine; fentanyl,* methadone,* meperidine,*
morphine,* oxycodone,* oxymorphone;* ibuprofen, naproxen, indomethacin;
prednisone, prednisolone

17

U.S. Food and Drug Administration Pregnancy Category System- C
Drugs

Amitriptyline; aspirin, ketorolac; betamethasone, cortisone; codeine,* propoxyphene,* hydrocodone;* gabapentin; lidocaine; propranolol; sumatriptan; sertraline, fluoxetine; bupropion

18

U.S. Food and Drug Administration Pregnancy Category System- D
Drugs

Imipramine; carbamazepine; diazepam; paroxetine; phenobarbital; phenytoin,
valproic acid

19

U.S. Food and Drug Administration Pregnancy Category System- X
Drugs

Ergotamine

20

Aspirin use during pregnancy may be associated with an
increased risk of

gastroschisis. Pregnant women should not use aspirin (.150 mg/day) regularly.

21

Ibuprofen and
naproxen during the first trimester

do not appear to be
teratogenic

22

Prostaglandin inhibitors have been associated with

narrowing of the ductus arteriosus in utero. Aspirin and
other prostaglandin inhibitors may decrease amniotic fluid
volume secondary to decreased fetal urine output, and they may prolong pregnancy and labor.

23

An increased incidence
of neonatal intracranial hemorrhage has been found in premature infants whose mothers ingested

aspirin near birth. For these reasons, full-dose aspirin and nonsteroidal antiinflammatory
drug (NSAID) therapy should be avoided in the third trimester. If a mild analgesic is indicated during pregnancy, acetaminophen is the drug of choice.

24

maternal opioid agonist or
agonist–antagonist exposure during pregnancy

There is no evidence that maternal opioid agonist or
agonist–antagonist exposure during pregnancy is teratogenic

25

Chronic in-utero exposure to opioids may lead to

neonatal abstinence syndrome.

26

treat mild or moderate pain during pregnancy

Acetaminophen combined
with hydrocodone or oxycodone may be used

27

maternal steroid use associated with

orofacial clefts

28

tricyclic
antidepressant drugs are

no evidence that tricyclic
antidepressant drugs are teratogenic

29

Exposure to SSRIs in the third
trimester before delivery may lead to a

neonatal withdrawal syndrome, and transient QT interval prolongation. An increased risk of persistent pulmonary hypertension syndrome
of the newborn

30

The anticonvulsants phenytoin, carbamazepine, and valproic acid all have been associated with

fetal dysmorphic
syndromes and should only be used when the risk
outweighs the benefit

31

Why is Ergotamine is contraindicated in pregnancy,

it may
be teratogenic, and it also causes uterine contractions

32

beta-blockers

they may be associated with intrauterine growth
retardation

33

amount of drug to which an infant is exposed during
lactation- Maternal factors

maternal dose and dosing
interval, the elimination half-life of the drug, the infant
nursing pattern (volume and timing), and the amount of
drug that actually crosses into breast milk.

34

The milk to plasma (M:P) ratio

is an index of the amount of drug that
is excreted into breast milk

35

Breast milk is slightly more
acidic than plasma, and therefore

passive diffusion favors
drugs that are weak bases, lipid soluble, and have low protein binding

36

volume of drugs in colostrum

Because the volume of colostrum is small, nursing neonates are exposed to minimal amounts of the drugs
administered to the mother in the postpartum period.

37

minimize infant exposure.

Administration of drugs shortly after nursing, and avoiding long-acting drugs

38

The following should
be considered when prescribing drugs to lactating
women

Is drug therapy really necessary?
The safest drug should be chosen, such as acetaminophen rather than aspirin for mild analgesia.
If there is a possibility of risk to the infant, then one should consider monitoring infant serum levels of the drug.
Having the mother take the medication just after she
has breast fed the infant or before the infant is due to
sleep can minimize drug exposure.

39

Acetaminophen

considered the safest analgesic for nursing mothers. The infant of a mother taking acetaminophen 4 g/day was exposed to less than 5% the
therapeutic infant dose

40

Opioid agonist and agonist–antagonists

cross freely into breast milk

41

opioids

compatible with breastfeeding

42

meperidine

Patient-controlled intravenous meperidine administered
for postcesarean delivery analgesia had a negative impact on neonatal neurobehavioral scores compared to morphine. The infants of nursing mothers ingesting opioids, particularly meperidine, should be monitored for adverse effects.

43

prednisone

Less than 1% of the maternal dose of prednisone or
prednisolone is recovered in breast milk.2 Even at high
maternal doses, this is unlikely to be enough to suppress
infant adrenal function

44

anticonvulsants

The anticonvulsants carbamazepine, phenytoin, and
valproic acid may be used safely during lactation

45

Risk Categories for Drugs for Nursing Infants -Drugs for which the effect on nursing infants is unknown but may
be of concern

Benzodiazepines, tricyclic antidepressants, buproprion, fluoxetine

46

Risk Categories for Drugs for Nursing Infants- Drugs that have been associated with significant effects on some
nursing infants and should be given to nursing mothers with caution

Aspirin, ergotamine

47

Risk Categories for Drugs for Nursing Infants- Maternal medication usually compatible with breast-feeding

Acetaminophen, anticonvulsants, beta-blockers, local anesthetics,
nonsteroidal anti-inflammatory drugs, opioid agonists, opioid
agonists–antagonists, steriods, sumatriptan, sertraline, paroxetine

48

Ergotamine

has been associated with neonatal convulsions and gastrointestinal disturbances and should not be used in nursing mothers

49

The two factors that determine the possible effects of radiation exposure on the developing fetus

gestational age and fetal dose of absorbed radiation.

50

Risks of fetal radiation exposure

abortion, genetic mutation,
and carcinogenesis

51

At doses of less than 50 mGy,

the risk of abnormalities is thought to be negligible; significant risk of malformation is increased only at doses
greater than 150 mGy

52

exposure should be avoided if possible until after

Although radiation exposure
from imaging studies generally falls below 50 mGy, exposure should be avoided if possible until after the 15th week of gestation since radiation can be lethal to the fetus or cause severe defects with doses as low as 50 mGy

53

MRI is indicated during
pregnancy when

other nonionizing imaging methods, such as ultrasonography, are unsatisfactory, and the information obtained would otherwise require exposure to ionizing
radiation

54

pelvic girdle pain

used to describe pain in the symphysis pubis and/or pain
in the regions of one or both sacroiliac (SI) joints and the
gluteal region, whereas pregnancy-related low back pain refers to pain in the lumbar region

55

Risk factors of pelvic girdle pain

strenuous work, previous low back pain, or pain syndromes in a previous pregnancy.

56

etiology of pelvic girdle pain

may be related to mechanical,
traumatic, hormonal, metabolic, or degenerative changes during pregnancy. Pain usually begins in the second trimester and resolves for most women
within several weeks to months of delivery.

57

Pelvic girdle pain is usually located between

the posterior
iliac crests near the SI joints.

58

treatments of pelvic girdle pain

Patient eduction, pelvic belts,
physiotherapy,and acupunture may be of benefit to some
patients

59

Medication of pelvic girdle pain

Acetaminophen is the drug of choice for minor pelvic and back pain. The short-term use of NSAIDs may be appropriate during the first and second trimesters. Severe back pain may require opioid therapy.
Epidural steroid injection(s) may be indicated for acute radicular pain consistent with lumbar nerve root
compression

Decks in Essentials of Pain Medicine Class (80):